Next-generation engineered constructs aim to overcome immunosuppressive tumor microenvironments in refractory malignancies
New framework aims to improve treatment for solid tumors
This systematic review synthesizes clinical data regarding CAR-T cells and bispecific antibodies for solid tumors and refractory malignancie…
Doctors are looking at new ways to use CAR-T cells and bispecific antibodies earlier in the treatment of hard-to-treat cancers.
CAR-T cell therapy for lymphoid malignancies presents a biphasic pattern of infectious complications
CAR-T Cell Therapy Shows Specific Patterns of Infection Risks
This narrative review examines the incidence patterns of bacterial, viral, and opportunistic infections in patients receiving CAR-T cell the…
Patients receiving CAR-T cell therapy for lymphoid malignancies may face different types of infections during early and late stages of treat…
Anti-CD19 shRNA-engineered CAR-T cells achieve an 88% overall response rate in B-cell acute lymphoblastic leukemia
CAR-T Cells Show Promise for B-cell Acute Lymphoblastic Leukemia
This meta-analysis evaluates anti-CD19 shRNA-engineered CAR-T cells (interleukin-6 knockdown) for patients with B-cell acute lymphoblastic l…
New research into modified CAR-T cells shows high response rates in patients with a specific type of leukemia while managing serious side ef…
CD19/BCMA CAR-T cells show early signal in six patients with refractory generalized myasthenia gravis
A One-Time Treatment Lets Patients with Severe Muscle Disease Stop Their Steroids
A Phase 1 study of 6 patients with refractory generalized myasthenia gravis found autologous CD19/BCMA CAR-T cells without prior lymphodeple…
A one-time infusion of engineered immune cells allowed patients with a debilitating muscle-weakening disease to stop steroids and live sympt…